RCOR2

Across TCGA pan-cancer cohorts, RCOR2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RCOR2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher RCOR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RCOR2 expression acts as an unfavorable survival marker.

THYM, BRCA, and KIRC are the cancer types where RCOR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	OS	Median	All	0.094	0.578	<.001	30	view →
KIRC	OS	Median	All	0.249	0.805	.010	12	view →
SKCM	OS	Median	III,IV	0.072	0.814	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	II,III,IV	0.487	0.867	.005	6	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RCOR2–THYM (OS)

Open the THYM breakdown →